CATALYST PHARMACEUTICALS INC (CPRX) Stock Overview
USA - NASDAQ:CPRX - US14888U1016 - Common Stock
CPRX Key Statistics, Chart & Performance
The current stock price of CPRX is 20.96 USD. In the past month the price increased by 7.38%. In the past year, price decreased by -2.33%.
CPRX Latest News, Press Relases and Analysis
CPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Company Info
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 181
Phone: 13055292522
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What does CATALYST PHARMACEUTICALS INC do?
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
What is the stock price of CATALYST PHARMACEUTICALS INC today?
The current stock price of CPRX is 20.96 USD. The price increased by 1.11% in the last trading session.
What is the dividend status of CATALYST PHARMACEUTICALS INC?
CPRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CPRX stock?
CPRX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
On which exchange is CPRX stock listed?
CPRX stock is listed on the Nasdaq exchange.
Can you provide the number of employees for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) currently has 181 employees.
When does CATALYST PHARMACEUTICALS INC (CPRX) report earnings?
CATALYST PHARMACEUTICALS INC (CPRX) will report earnings on 2025-11-05, after the market close.
CPRX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX is a bad performer in the overall market: 68.6% of all stocks are doing better.
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to CPRX. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.65. The EPS increased by 205.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.36% | ||
| ROA | 21.47% | ||
| ROE | 24.38% | ||
| Debt/Equity | 0 |
CPRX Forecast & Estimates
14 analysts have analysed CPRX and the average price target is 34.68 USD. This implies a price increase of 65.46% is expected in the next year compared to the current price of 20.96.
For the next year, analysts expect an EPS growth of 13.37% and a revenue growth 16.03% for CPRX